Search the Newsreel

Net income before discontinued operations of Humana Inc. – HAM:HUM

This article focuses on the net income before discontinued operations for Humana Inc. (HUM) on the Hamburg Stock Exchange. The content appears to be a financial data page from TradingView, indicating that the market is closed with no trades recorded. The page provides a …

Ihuman Inc (IH) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Ihuman Inc (IH). It indicates that the company has distributed a total of $0.00 in dividends over the past 5 years and currently shows no upcoming dividend data. The page also presents basic stock information …

Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of Humacyte Inc (HUMA), listing major institutional shareholders and their proportional holdings. It also provides a breakdown of shareholder types and historical institutional shareholding data from Q1 2023 to Q1 2026, alongside information on related ETFs.

Lawsuit against Humana moves forward over alleged misleading cost statements, stock dropped 22% in 2024

A securities fraud lawsuit against Humana Inc. and its former CEO and CFO is progressing, with a judge validating key claims. The lawsuit alleges that Humana misled investors about rising healthcare utilization costs between July 2022 and October 2024, leading to an inflated stock …

Humana Inc. (NYSE: HUM) Investor Reminder: Schubert Jonckheer Investigating Possible False Statements Following 22% Stock Drop

Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Humana Inc. (HUM) for alleged false and misleading statements regarding the company's exposure to increased healthcare utilization costs, which led to a 22% stock drop. A U.S. District Judge ruled that key claims …

Maharah Human Resources Co. Revenue Breakdown – TADAWUL:1831

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Humacyte has announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The company plans to initiate a Phase 2a study in ten adult …

Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass

Humacyte (Nasdaq: HUMA) has received FDA acceptance for its Investigational New Drug (IND) application, paving the way for a first-in-human Phase 2a clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, expected to enroll ten adult …

Bronstein, Gewirtz & Grossman, LLC Encourages Humana Inc. (HUM) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Humana Inc. (HUM) regarding potential corporate wrongdoing. The firm is encouraging Humana stockholders who purchased securities before June 27, 2022, and still hold them, to contact them to assist with the investigation. The firm …

Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery

Humacyte, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its Coronary Tissue Engineered Vessel (CTEV). This study will evaluate the CTEV for use in Coronary Artery Bypass Grafting (CABG) surgery. The company …

Caxton Associates LLP Makes New Investment in Humana Inc. $HUM

Caxton Associates LLP has acquired a new stake in Humana Inc. by purchasing 5,646 shares worth approximately $979,000 in the first quarter. Several other institutional investors, including State of Wyoming, Kopernik Global Investors LLC, and Westpac Banking Corp, also adjusted their positions in Humana. …

Bank of Nova Scotia Sells 308,864 Shares of Humana Inc. $HUM

Bank of Nova Scotia significantly reduced its stake in Humana Inc. by selling 308,864 shares, decreasing its position by 85.6% in the first quarter. Despite this, other institutional investors have increased their holdings. Humana reported strong Q1 earnings, beating analyst estimates, and has received …

IH|Ihuman Inc|Price:1.335|Chg%:-0.045

This article provides a company profile for iHuman Inc (IH), detailing its engagement in tech-powered educational products for children, including interactive apps and offline materials. It lists key company information such as its CEO, IPO date, and executive team. The article also touches upon …

iHuman Inc. Revenue Breakdown – NYSE:IH

This article provides a revenue breakdown for iHuman Inc. (NYSE:IH), highlighting that the majority of its revenue comes from China. In the last year, China contributed $112.27 million USD, which was a decrease from $128.14 million USD the previous year. The information is sourced …

Ihuman Inc (IH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The TradingKey report focuses on Ihuman Inc (IH) and its revenue breakdown, specifically noting that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company for the fiscal years available (FY2019-FY2024). It highlights that Ihuman …

Weiss Asset Management LP Buys 12,685 Shares of Humana Inc. $HUM

Weiss Asset Management LP increased its stake in Humana Inc. by 45% in the first quarter, purchasing an additional 12,685 shares, bringing their total holdings to 40,891 shares valued at approximately $7.09 million. The increase follows Humana's strong quarterly results, where it exceeded EPS …

Healthcare of Ontario Pension Plan Trust Fund Raises Stock Position in Humana Inc. $HUM

Healthcare of Ontario Pension Plan Trust Fund significantly increased its stake in Humana Inc. by 3,350.6% in the first quarter, now owning 336,572 shares valued at $58,358,000. Other institutional investors like Vanguard Group Inc., Capital International Investors, Pzena Investment Management LLC, State Street Corp, …

HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014

Humacyte Inc. (HUMA) is a biotechnology company developing universally implantable bioengineered human tissues. The company is in late-stage clinical trials for vascular applications like hemodialysis and peripheral artery disease, and also has preclinical development in other areas. Trading at $0.625, the article provides an …

Ihuman Inc (IH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Ihuman Inc (IH), listing major institutional shareholders such as Morgan Stanley, Citadel Advisors, and Acadian Asset Management, along with their respective holdings and proportions. It also presents a historical overview of institutional shareholding from 2023Q4 to 2026Q1, …

Price to sales forward of Humacyte, Inc. – NASDAQ:HUMAW

This article from TradingView provides financial information for Humacyte, Inc. (NASDAQ: HUMAW), specifically focusing on its price-to-sales forward metric. The content highlights a specific period, value, and change percentage for this financial indicator, framed within a market data and analysis platform context.

Ihuman Inc (IH) Cash Flow

This article provides an overview of Ihuman Inc's cash flow statement, detailing its operating, investing, and financing cash flows. It highlights that Ihuman Inc generated $7.44M in operating cash flow in fiscal 2025 and spent $710.79K on capital expenditures in the most recent quarter. …

Humana Inc. Revenue Breakdown – NYSE:HUM

Humana Inc.'s revenue reached $129.66 billion USD last year, primarily driven by its Insurance segment which generated $124.56 billion USD. The majority of this revenue, $129.66 billion USD, originated from operations within the United States. This indicates a strong performance in its core insurance …

Humana Inc. stock underperforms Friday when compared to competitors

Humana Inc. (HUM) shares fell 1.31% to $389.32 on Friday, despite a positive trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average seeing gains. This marks the third consecutive day of losses for the stock.

Can Humana Beat Q2 Earnings Estimates on Growing Premiums?

Humana (HUM) is expected to announce its Q2 2026 earnings on July 29, with analysts predicting a slight year-over-year decrease in EPS but significant revenue growth due to increasing premiums. The company has a positive Earnings ESP and a Zacks Rank #1, suggesting a …

KBC Group NV Trims Holdings in Humana Inc. $HUM

KBC Group NV reduced its stake in Humana Inc. by 27.4% in the first quarter, selling 11,584 shares and retaining 30,718 shares valued at $5.33 million. Despite analyst caution with an average "Hold" rating and a $327.17 price target, Humana reported strong Q1 earnings …

Kopernik Global Investors LLC Takes Position in Humana Inc. $HUM

Kopernik Global Investors LLC has acquired a new stake in Humana Inc. (NYSE:HUM) during the first quarter, purchasing 113,385 shares valued at approximately $19.66 million. This investment positions Humana as the 21st biggest holding for Kopernik, representing about 1.4% of its portfolio. Other institutional …

SEB Asset Management AB Purchases Shares of 24,228 Humana Inc. $HUM

SEB Asset Management AB acquired 24,228 shares of Humana Inc. (NYSE:HUM) in the first quarter, valued at approximately $4.2 million. Other institutional investors like Swiss National Bank and Watershed Asset Management also adjusted their positions in the insurance provider. Humana reported strong Q1 earnings, …

Humana Inc (HUM) extends 12-week advance to 86.3%

The healthcare-plan stock is still trending higher, though relative strength remains moderate rather than emphatic.

Humana 401(k) Forfeiture Challenge Paused for Appeals Court Say

A lawsuit concerning how Humana Inc. manages forfeited contributions in its 401(k) plan has been put on hold. The pause is awaiting a decision from the US Court of Appeals for the Sixth Circuit in a related case, Donelson v. Meijer Inc., which is …

Humana (HUM) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street expects a year-over-year decline in earnings on higher revenues when Humana (HUM) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Meeder Asset Management Inc. Sells 5,762 Shares of Humana Inc. $HUM

Meeder Asset Management Inc. significantly reduced its holdings in Humana Inc. (NYSE:HUM) by 79.6% in the first quarter, selling 5,762 shares and retaining 1,476 shares valued at $256,000. Other institutional investors, however, increased their positions in Humana. The insurance provider reported strong first-quarter earnings, …

Humana Inc. $HUM Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System reduced its stake in Humana Inc. by 24.4% in the first quarter, selling 55,174 shares and owning approximately $29.68 million worth of the company's stock. Despite some institutional selling, other firms increased their holdings in Humana. The article also …

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) saw its stock close at $0.67, a 2.22% increase, outperforming the S&P 500's daily gain, despite a 21.82% drop over the past month. Analysts project a significant increase in EPS and revenue for the upcoming release and the full year, with …

Humana (HUM) is a Great Momentum Stock: Should You Buy?

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) experienced a larger drop than the general market, closing down 1.28% against a backdrop of slight S&P 500 and Nasdaq depreciation, and a 0.59% Dow downswing. The company's stock has fallen 28.09% in the past month, underperforming the Medical sector and …

Humana Inc. $HUM Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp significantly reduced its stake in Humana Inc. (NYSE:HUM) by 70.6% in the first quarter, selling 1,479,679 shares and now owning 614,891 shares valued at $106.6 million. Despite this, other institutional investors have either increased or initiated positions in …